Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Lalla RV, Sonis S, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin North Am. 2008;52:61–viii.

    Article  Google Scholar 

  2. Van Sebille YZ, Stansborough R, Wardill HR, Bateman E, Gibson RJ, Keefe DM. Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr Oncol Rep. 2015;17:50.

    Article  Google Scholar 

  3. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR, et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2013;48:99–104.

    CAS  Article  Google Scholar 

  4. Spielberger R, Stiff PJ, Bensinger WI, Gentile M, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590.

    CAS  Article  Google Scholar 

  5. Nooka AK, Johnson HR, Kaufman JL, Flowers CR, Langston A, Steuer C, et al. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:852–7.

    CAS  Article  Google Scholar 

  6. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.

    Article  Google Scholar 

  7. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8:33–9.

    CAS  Article  Google Scholar 

  8. McDonnell AM, Lenz KL. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. Ann Pharmacother. 2006;40:86–94.

    Google Scholar 

  9. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006;108:3216–22.

    CAS  Article  Google Scholar 

  10. Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Gluck S, Brizel HE, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol. 2008;26:2489–96.

    CAS  Article  Google Scholar 

  11. Danilenko AM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol. 1999;27:64–71.

    CAS  Article  Google Scholar 

  12. Dorr W, Heider K, Spekl K. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int J Radiat Biol. 2005;81:557–65.

    Article  Google Scholar 

  13. Zia-Amirhosseini P, Salfi M, Leese P, Yates W, Danilenko DM, Ring B, et al. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharm Ther. 2006;79:558–69.

    CAS  Article  Google Scholar 

  14. Sonis S, Eilers JP, Epstein J, LeVeque FG, Liggett WH Jr, Mulagha MT, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis. Cancer. 1999;85:2103–13.

    CAS  Article  Google Scholar 

  15. Blijlevens N, de Chateau M, Krivan G, Rabitsch W, Szomor A, Pytlik R, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden. Bone Marrow Transplant. 2013;48:966–71.

    CAS  Article  Google Scholar 

  16. Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant. 2016;22:605–16.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

All authors conceived and designed the work that led to the submission, acquired data, played an important role in interpreting the results, drafted and revised the manuscript, approved the final version and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JC was responsible for designing the study protocol, collecting and analysing the data, formulating the discussion, drafting, revising and finalising the manuscript. MD was responsible for designing the study protocol, interpreting the data, drafting, revising and finalising the manuscript. CMK was responsible for designing the study protocol, interpreting the data, drafting, revising and finalising the manuscript. SA was responsible for designing the study protocol, interpreting the data and revising the manuscript. RH was responsible for designing the study protocol, data collection, formatting the tables and figures and revising the manuscript. AS was responsible for designing the study protocol, interpreting the data, revising and finalising the manuscript.

Corresponding author

Correspondence to John Coutsouvelis.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Coutsouvelis, J., Dooley, M., Kirkpatrick, C.M. et al. Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning. Bone Marrow Transplant 57, 1329–1331 (2022). https://doi.org/10.1038/s41409-022-01714-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01714-6

Search

Quick links